JP2010503386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503386A5 JP2010503386A5 JP2009527737A JP2009527737A JP2010503386A5 JP 2010503386 A5 JP2010503386 A5 JP 2010503386A5 JP 2009527737 A JP2009527737 A JP 2009527737A JP 2009527737 A JP2009527737 A JP 2009527737A JP 2010503386 A5 JP2010503386 A5 JP 2010503386A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- seq
- chain
- fab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 9
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 6
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 6
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019399A EP1900752A1 (en) | 2006-09-15 | 2006-09-15 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| EP06019399.2 | 2006-09-15 | ||
| PCT/EP2007/007944 WO2008031577A1 (en) | 2006-09-15 | 2007-09-12 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010503386A JP2010503386A (ja) | 2010-02-04 |
| JP2010503386A5 true JP2010503386A5 (cg-RX-API-DMAC7.html) | 2010-10-14 |
| JP5513114B2 JP5513114B2 (ja) | 2014-06-04 |
Family
ID=37737768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527737A Active JP5513114B2 (ja) | 2006-09-15 | 2007-09-12 | 卵巣癌の放射免疫療法のためのヒト抗−葉酸受容体アルファ抗体および抗体フラグメント |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8388972B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1900752A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5513114B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101497045B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007296899B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0716811B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2662005C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2644423T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL197300A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009002711A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ575093A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2464277C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008031577A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200901328B (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| EP3401333B1 (en) | 2010-09-09 | 2021-05-19 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
| RU2630608C2 (ru) * | 2010-11-05 | 2017-09-11 | Морфотек Инк. | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| EP2687231A4 (en) | 2011-03-18 | 2014-10-22 | Univ Kagoshima | COMPOSITION FOR THE TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER |
| CA2831426C (en) * | 2011-04-01 | 2023-02-21 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
| PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| MX356947B (es) | 2011-08-23 | 2018-06-20 | Roche Glycart Ag | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. |
| US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| CN104755498B (zh) * | 2012-08-31 | 2019-06-18 | 伊缪诺金公司 | 用于检测叶酸受体1的诊断测定和试剂盒 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US9637547B2 (en) * | 2013-08-30 | 2017-05-02 | Immunogen, Inc. | Monoclonal antibodies for detection of folate receptor 1 |
| SG10202102555TA (en) * | 2013-10-08 | 2021-04-29 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| KR101646577B1 (ko) * | 2014-08-14 | 2016-08-09 | 원광대학교산학협력단 | 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물 |
| LT3221357T (lt) | 2014-11-20 | 2020-08-25 | F. Hoffmann-La Roche Ag | Bendros lengvosios grandinės ir naudojimo būdai |
| HRP20201928T1 (hr) | 2014-11-20 | 2021-02-05 | F. Hoffmann - La Roche Ag | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 |
| MX2017006571A (es) | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
| IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| CA3177187A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2019094648A1 (en) | 2017-11-08 | 2019-05-16 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| MX2020009522A (es) | 2018-03-13 | 2020-10-22 | Phanes Therapeutics Inc | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| CA3138272A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
| EP4010031A1 (en) | 2019-08-06 | 2022-06-15 | L.E.A.F Holdings Group LLC | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
| CN119757601A (zh) * | 2025-01-06 | 2025-04-04 | 哈尔滨脉图精准技术有限公司 | 一种用于卵巢癌诊断的代谢标志物组合及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US20050232919A1 (en) * | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP1945772B1 (en) * | 2005-10-06 | 2015-11-18 | Advanced Accelerator Applications S.A. | Novel selection system |
-
2006
- 2006-09-15 EP EP06019399A patent/EP1900752A1/en not_active Withdrawn
-
2007
- 2007-09-12 JP JP2009527737A patent/JP5513114B2/ja active Active
- 2007-09-12 US US12/441,207 patent/US8388972B2/en active Active
- 2007-09-12 KR KR1020097004948A patent/KR101497045B1/ko active Active
- 2007-09-12 MX MX2009002711A patent/MX2009002711A/es not_active Application Discontinuation
- 2007-09-12 WO PCT/EP2007/007944 patent/WO2008031577A1/en not_active Ceased
- 2007-09-12 NZ NZ575093A patent/NZ575093A/en unknown
- 2007-09-12 RU RU2009114161/10A patent/RU2464277C2/ru active
- 2007-09-12 ES ES07802280.3T patent/ES2644423T3/es active Active
- 2007-09-12 AU AU2007296899A patent/AU2007296899B2/en active Active
- 2007-09-12 EP EP07802280.3A patent/EP2061813B1/en active Active
- 2007-09-12 BR BRPI0716811A patent/BRPI0716811B8/pt active IP Right Grant
- 2007-09-12 CA CA2662005A patent/CA2662005C/en active Active
- 2007-09-12 ZA ZA200901328A patent/ZA200901328B/xx unknown
-
2009
- 2009-02-26 IL IL197300A patent/IL197300A/en active IP Right Grant